Reporting of clinical trial uncertainties with new cancer drugs in journal publications and clinical guidelines
Cherla, A., Wagner, A. K., Wouters, O. J.
, Woloshin, S., Davis, C., Mossialos, E. & Naci, H.
(2025).
Reporting of clinical trial uncertainties with new cancer drugs in journal publications and clinical guidelines.
JAMA,
334(16), 1480 - 1482.
https://doi.org/10.1001/jama.2025.13917
, Woloshin, S., Davis, C., Mossialos, E. & Naci, H.
(2025).
Reporting of clinical trial uncertainties with new cancer drugs in journal publications and clinical guidelines.
JAMA,
334(16), 1480 - 1482.
https://doi.org/10.1001/jama.2025.13917
This study assesses the reporting by journal publications and National Comprehensive Cancer Network (NCCN) guidelines of clinical uncertainties identified by the US Food and Drug Administration’s (FDA) Benefit-Risk Framework pertaining to cancer drugs approved in 2019-2022.
